非小細胞肺がん：グローバル医薬品市場（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 9
1.1 List of Tables 16
1.2 List of Figures 22
2 Introduction 24
2.1 Catalyst 24
2.2 Related Reports 25
2.3 Upcoming Related Reports 25
3 Disease Overview 26
3.1 Etiology and Pathophysiology 26
3.1.1 Etiology 26
3.1.2 Pathophysiology and Histology 26
3.1.3 NSCLC Biomarkers 27
3.1.4 Quality of Life 28
3.2 Symptoms 29
4 Epidemiology 31
4.1 Risk Factors and Comorbidities 32
4.1.1 Smokers are more likely to have lung cancer than non-smokers 33
4.1.2 Long-term exposure to radon increases the risk of lung cancer 35
4.1.3 Family history of any cancer increases lung cancer risk 35
4.1.4 TB increases the risk of lung cancer and increases mortality risk 35
4.1.5 COPD is a comorbidity that reduces lung cancer survival 36
4.1.6 Lung cancer screening programs may not be beneficial 36
4.1.7 Stage at diagnosis significantly impacts the survival of lung cancer cases 37
4.2 Global Trends 38
4.2.1 US 41
4.2.2 France 46
4.2.3 Germany 47
4.2.4 Italy 49
4.2.5 Spain 51
4.2.6 UK 53
4.2.7 Japan 54
4.2.8 China 56
4.2.9 India 58
4.3 Forecast Methodology 60
4.3.1 Sources Used 62
4.3.2 Sources Not Used 67
4.3.3 Forecast Assumptions and Methods 67
4.4 Epidemiology Forecast (2012-2022) 70
4.4.1 Incident/Prevalent Cases of NSCLC 70
4.4.2 Age-Specific Incident Cases of NSCLC 72
4.4.3 Sex-Specific Incident Cases of NSCLC 73
4.4.4 Age-Standardized Incidence Rates of NSCLC 75
4.4.5 Segmentation of NSCLC Incident Cases 76
4.5 Discussion 84
4.5.1 Limitations of the Analysis 85
4.5.2 Strengths of the Analysis 86
5 Disease Management 87
5.1 Treatment Overview 87
5.1.1 Diagnosis 88
5.1.2 Clinical Staging 89
5.1.3 Screening and Early Detection 91
5.1.4 Localized Procedures and Therapies 92
5.1.5 Systemic Chemotherapy 93
5.1.6 Targeted Therapy 93
5.2 US 96
5.2.1 Diagnosis 96
5.2.2 Clinical Practice 96
5.3 France 98
5.3.1 Diagnosis 98
5.3.2 Clinical Practice 99
5.4 Germany 100
5.4.1 Diagnosis 100
5.4.2 Clinical Practice 101
5.5 Italy 103
5.5.1 Diagnosis 103
5.5.2 Clinical Practice 104
5.6 Spain 105
5.6.1 Diagnosis 105
5.6.2 Clinical Practice 105
5.7 UK 106
5.7.1 Diagnosis 106
5.7.2 Clinical Practice 107
5.8 Japan 108
5.8.1 Diagnosis 108
5.8.2 Clinical Practice 109
5.9 China 110
5.9.1 Diagnosis 110
5.9.2 Clinical Practice 111
5.10 India 112
5.10.1 Diagnosis 112
5.10.2 Clinical Practice 112
6 Competitive Assessment 115
6.1 Overview 115
6.2 Strategic Competitor Assessment 116
6.3 Product Profiles – Major Brands, Chemotherapies 118
6.3.1 Alimta (pemetrexed disodium) 118
6.3.2 Abraxane (nab-paclitaxel) 123
6.4 Product Profiles – Major Brands, Targeted Therapies 127
6.4.1 Avastin (bevacizumab) 127
6.4.2 Gilotrif (afatinib) 132
6.4.3 Iressa (gefitinib) 138
6.4.4 Tarceva (erlotinib hydrochloride) 143
6.4.5 Xalkori (crizotinib) 149
7 Opportunity and Unmet Need 156
7.1 Overview 156
7.2 Improved Overall Survival and Less Toxicity 157
7.3 Treatments for Patients with Acquired TKI Resistance 158
7.4 Better Treatment Options for Squamous Patients 158
7.5 Preventing Relapse or Recurrence 159
7.6 More Efficacious Second-Line Therapies 159
7.7 Increased Availability of Mutation Testing 160
7.8 More Cost-Effective Therapies 160
7.9 Unmet Needs Gap Analysis 161
8 Pipeline Assessment 165
8.1 Overview 165
8.2 Clinical Trial Mapping 165
8.2.1 Clinical Trials by Country 165
8.3 Clinical Trials by Phase and Trial Status 167
8.4 Promising Drugs in Clinical Development 168
8.4.1 Onartuzumab (MetMab) 172
8.4.2 Necitumumab (IMC-11F8) 177
8.4.3 Ramucirumab (IMC-1121B) 183
8.4.4 Custirsen (OGX-011) 188
8.4.5 Ganetespib (STA-9090) 194
8.4.6 Nintedanib (BIBF1120) 201
8.4.7 Dacomitinib (PF-00299804) 206
8.4.8 LDK378 (ceritinib) 211
8.4.9 Yervoy (ipilimumab) 217
8.4.10 Nivolumab (BMS936558) 222
8.4.11 MPDL3280A (RG7446) 230
8.4.12 GSK1572932A (MAGE-A3 Cancer Immunotherapy) 233
8.4.13 Halaven (eribulin mesylate) 237
9 Current and Future Players 243
9.1 Overview 243
9.2 Trends in Corporate Strategy 245
9.3 Company Profiles 246
9.3.1 Roche/Genentech 246
9.3.2 Pfizer 249
9.3.3 Bristol-Myers Squibb 251
9.3.4 Eli Lilly 254
9.3.5 Boehringer Ingelheim 257
9.3.6 Novartis 259
10 Market Outlook 261
10.1 Global Markets 261
10.1.1 Forecast 261
10.1.2 Drivers and Barriers – Global Issues 265
10.2 United States 269
10.2.1 Forecast 269
10.2.2 Key Events 273
10.2.3 Drivers and Barriers 274
10.3 France 277
10.3.1 Forecast 277
10.3.2 Key Events 281
10.3.3 Drivers and Barriers 282
10.4 Germany 284
10.4.1 Forecast 284
10.4.2 Key Events 288
10.4.3 Drivers and Barriers 289
10.5 Italy 291
10.5.1 Forecast 291
10.5.2 Key Events 295
10.5.3 Drivers and Barriers 295
10.6 Spain 297
10.6.1 Forecast 297
10.6.2 Key Events 300
10.6.3 Drivers and Barriers 301
10.7 United Kingdom 302
10.7.1 Forecast 302
10.7.2 Key Events 306
10.7.3 Drivers and Barriers 307
10.8 Japan 309
10.8.1 Forecast 309
10.8.2 Key Events 313
10.8.3 Drivers and Barriers 313
10.9 China 316
10.9.1 Forecast 316
10.9.2 Key Events 320
10.9.3 Drivers and Barriers 320
10.10 India 323
10.10.1 Forecast 323
10.10.2 Key Events 327
10.10.3 Drivers and Barriers 327
11 Appendix 329
11.1 Bibliography 329
11.2 Abbreviations 360
11.3 Methodology 365
11.4 Forecasting Methodology 365
11.4.1 Number of NSCLC Patients Currently Seeking Treatment 365
11.4.2 Percent Drug-Treated Patients 366
11.4.3 Drugs Included in Each Therapeutic Class 366
11.4.4 Launch and Patent Expiry Dates 367
11.4.5 General Pricing Assumptions 368
11.4.6 Individual Drug Assumptions 371
11.4.7 Generic Erosion 381
11.4.8 Pricing of Pipeline Agents 381
11.5 Physicians and Specialists Included in This Study 383
11.6 Survey of Prescribing Physicians 385
11.7 About the Authors 386
11.7.1 Authors 386
11.7.2 Epidemiologists 387
11.7.3 Global Head of Healthcare 388
11.8 About GlobalData 389
11.9 Disclaimer 389